Representative before the EPO

Technology company logo thumb
no operation time available
3 offices
Technology Company

David O'Connor has worked on the following 29 EPO patent applications which have been published in the last five years:

EP11713416

ANTIBODIES AGAINST CSF-1R

IPC classification:
A61K 39/395, A61P 35/00, A61P 35/02, C07K 16/28, C07K 16/32
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
The patent has been granted
EP11792989

CGRP ANTIBODIES

IPC classification:
A61K 39/395, C07K 16/26
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP12712874

VARIANTS OF HUMAN GDNF

IPC classification:
A61K 38/18, C07K 14/475
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP12766847

FIBROBLAST GROWTH FACTOR 21 VARIANTS

IPC classification:
A61K 38/18, C07K 14/50
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP12795981

ANTI-GLUCAGON ANTIBODIES AND USES THEREOF

IPC classification:
C07K 16/26
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13157487

Novel imaging agents for detecting neurological dysfunction

IPC classification:
C07B 59/00
Applicant:
Eli Lilly and Company Limited
Applicant:
Siemens Molecular Imaging, Inc.
Agent:
Olaf Bruns, Siemens AG
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12712049

ANTIBODIES THAT BIND TGF-ALPHA AND EPIREGULIN

IPC classification:
A61K 39/00, C07K 16/22
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13726321

ANTI-BAFF-ANTI-IL-17 BISPECIFIC ANTIBODIES

IPC classification:
C07K 16/24, C07K 16/28, C07K 16/46
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP13712005

2-AMINO, 6-PHENYL SUBSTITUTED PYRIDO [2, 3 - D]PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS

IPC classification:
A61K 31/519, A61P 35/00, C07D 471/04, C07D 471/12
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP13724685

THERAPEUTIC USES OF FIBROBLAST GROWTH FACTOR 21 PROTEINS

IPC classification:
A61K 38/18, A61P 19/08, A61P 19/10
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP12783780

CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION

IPC classification:
A61K 49/10, A61K 51/04, C07B 59/00, C07D 209/88, C07D 403/12, C07D 471/04, C07D 471/14
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP13730733

FIBROBLAST GROWTH FACTOR 21 PROTEINS

IPC classification:
A61K 38/18, C07K 14/50
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
GRANT OF PATENT INTENDED
EP13729210

FIBROBLAST GROWTH FACTOR 21 VARIANTS

IPC classification:
A61K 38/18, C07K 14/50
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP13802786

6-((S)-1-{1-[5-(2-HYDROXY-ETHOXY)-PYRIDIN-2-YL]-1H-PYRAZOL-3-YL}-ETHYL)-3H-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST

IPC classification:
A61K 31/4439, A61P 25/04, A61P 25/08, C07D 417/14
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP13765974

PREPARATION OF LIVE VACCINES

IPC classification:
A61K 39/02, A61K 39/112, C12R 1/42
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
GRANT OF PATENT INTENDED
EP13818045

BMP-6 ANTIBODIES

IPC classification:
A61K 39/395, A61P 7/06, C07K 16/22
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
PATENT GRANTED
EP14761062

ANTIBODIES THAT BIND IL-23

IPC classification:
A61K 39/395
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP14719931

METHODS FOR PRODUCING FABS AND BI-SPECIFIC ANTIBODIES

IPC classification:
C07K 16/00
Applicant:
Eli Lilly and Company Limited
Applicant:
The University of North Carolina at Chapel Hill
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP14722408

THERAPEUTIC USES FOR VEGFR1 ANTIBODIES

IPC classification:
A61K 39/395, A61P 13/12, C07K 16/28
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP14783708

COMPOUNDS AND THEIR USE FOR PREPARATION OF TAU IMAGING AGENTS AND TAU IMAGING FORMULATIONS

IPC classification:
A61K 31/437, A61P 25/28, C07D 471/04, G01N 33/68
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP11754805

ANTI-VEGFR-3 ANTIBODY COMPOSITIONS

IPC classification:
C07K 16/28
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP14824266

COMPOUNDS TO FIBROBLAST GROWTH FACTOR RECEPTOR-3 (FGFR3) AND THERAPEUTIC USES

IPC classification:
A61K 31/559, A61K 47/48, A61P 35/00, C07K 16/28, G01N 33/574
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION IN PROGRESS
EP15709024

ANTI-MET IN COMBINATION WITH ANTI-VEGFR2 ANTIBODIES THERAPY FOR CANCER

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28, C07K 16/30
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15724469

VEGFR2/ANG2 COMPOUNDS

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/22, C07K 16/28, C07K 16/46
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15796232

ANG2 ANTIBODIES

IPC classification:
A61K 39/395
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP15726843

6-SUBSTITUTED-3H-1,3-BENZOTHIAZOL-2-ONE COMPOUNDS AS TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONISTS

IPC classification:
A61K 31/41, A61P 25/00, C07D 417/14
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP16196811

ANTIBODIES AGAINST CSF-1R

IPC classification:
A61K 39/00, A61K 39/395, A61K 45/06, A61P 35/00, A61P 35/02, C07K 16/28, C07K 16/32
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
APPLICATION PUBLISHED
EP15754347

ANTI-VEGFR2 ANTIBODY THERAPY FOR HEPATOCELLULAR CARCINOMA

IPC classification:
A61K 39/395, A61P 35/00, C07K 16/28, C07K 16/30, G01N 33/574
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
EXAMINATION REQUESTED
EP17153380

ANTI-BAFF-ANTI-IL-17 BISPECIFIC ANTIBODIES

IPC classification:
C07K 16/24, C07K 16/28, C07K 16/46
Applicant:
Eli Lilly and Company Limited
Agent:
David O'Connor, Eli Lilly and Company Limited
Status:
The application has been published

Please Sign in to use this feature